Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
259 hedge funds and large institutions have $1.47B invested in Catalyst Pharmaceutical in 2023 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 93 increasing their positions, 84 reducing their positions, and 43 closing their positions.
2,344% more call options, than puts
Call options by funds: $43M | Put options by funds: $1.76M
11% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 84
2.34% more ownership
Funds ownership: 80.85% → 83.19% (+2.3%)
9% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 43
1% more funds holding
Funds holding: 257 → 259 (+2)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3% less capital invested
Capital invested by funds: $1.52B → $1.47B (-$48.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$73.8M |
| 2 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$22.7M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$18.2M |
| 4 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$8.48M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$15.8M |
| 2 |
Man Group
London,
United Kingdom
|
-$14.7M |
| 3 |
Two Sigma Investments
New York
|
-$12.2M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$10.9M |
| 5 |
D.E. Shaw & Co
New York
|
-$7.33M |
CPRX Hedge Fund Activity: Q1 2023 in Review
259 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2023, worth a combined $1.47B — down 3.2% from $1.52B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new CPRX positions and 43 closed out — a net gain of 4 holders — while 93 added to existing stakes and 84 trimmed.
The largest buyer was Deerfield Management, adding an estimated $73.8M. The largest seller was Millennium Management, cutting an estimated $15.8M.
- 259 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2023, up from 257 in Q4 2022.
- Funds reported $1.47B of Catalyst Pharmaceutical stock for Q1 2023, down 3.2% quarter-over-quarter.
- 47 funds opened new Catalyst Pharmaceutical positions in Q1 2023 and 43 closed out, a net change of +4 holders.
- The largest Catalyst Pharmaceutical buyer in Q1 2023 was Deerfield Management, an estimated $73.8M added.
- The largest Catalyst Pharmaceutical seller in Q1 2023 was Millennium Management, an estimated $15.8M sold.
Based on aggregated 13F filings for Q1 2023.